# Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy

> **NCT02068443** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 374 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin
- **DRUG:** Metformin hydrochloride
- **DRUG:** Metformin hydrochloride Placebo

## Key facts

- **NCT ID:** NCT02068443
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 374 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02068443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02068443, "Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02068443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*